News, Events & Resources
There’s a lot happening at Melinta. We are the company of the moment and enterprise of the future. Join us in realizing our vision — this is our story, and it’s going to be legendary.
Melinta Therapeutics Announces Two Key Milestones Expanding Reimbursement and Access for KIMYRSA™ (oritavancin)
KIMYRSA™ Receives Product-Specific J-Code and Transitional Pass-Through Status from CMS
Melinta Therapeutics and Hikma sign exclusive licensing agreement for two novel anti-infectives for the Middle East and North Africa region
Melinta Therapeutics and Hikma sign exclusive licensing agreement for two novel anti-infectives for the Middle East and North Africa region
Melinta Therapeutics (Melinta) and Hikma Pharmaceuticals PLC (Hikma) today announced they have entered into an exclusive licensing agreement for...
Melinta Therapeutics Announces FDA Approval of KIMYRSA™ (oritavancin)
Melinta Therapeutics Announces FDA Approval of KIMYRSA™ (oritavancin)
The efficacy and safety of KIMYRSA were established in the SOLO clinical trials with another oritavancin product, ORBACTIV®...
Melinta Therapeutics Announces Appointment of John Harlow as Chief Commercial Officer
Melinta Therapeutics Announces Appointment of John Harlow as Chief Commercial Officer
Melinta Therapeutics, LLC (“Melinta”), a commercial-stage company focused on the development and commercialization of novel...